Sistema de Salut de Catalunya
[Torres-Salido MT] Internal Medicine Department, Hospital Quironsalud del Vallés, Sabadell, Spain. [Sanchis M, Solé C, Ordi-Ros J, Cortés-Hernández J] Unitat del Lupus, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Reumatologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Moliné T, Vidal M] Servei de Patologia Renal, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Vidal X] Servei Farmacologia Clínica, Fundació Institut Català de Farmacologia, Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain.
Vall d'Hebron Barcelona Hospital Campus
2020-07-06T13:03:45Z
2020-07-06T13:03:45Z
2019-09-17
Neuropilin-1; Lupus nephritis; Urinary biomarker
Neuropilina-1; Nefritis lúpica; Biomarcador urinario
Neuropilina-1; Nefritis per lupus; Biomarcador urinari
At present, Lupus Nephritis (LN) is still awaiting a biomarker to better monitor disease activity, guide clinical treatment, and predict a patient’s long-term outcome. In the last decade, novel biomarkers have been identified to monitor the disease, but none have been incorporated into clinical practice. The transmembrane receptor neuropilin-1 (NRP-1) is highly expressed by mesangial cells and its genetic deletion results in proteinuric disease and glomerulosclerosis. NRP-1 is increased in kidney biopsies of LN. In this work we were interested in determining whether urinary NRP-1 levels could be a biomarker of clinical response in LN. Our results show that patients with active LN have increased levels of urinary NRP-1. When patients were divided according to clinical response, responders displayed higher urinary and tissue NRP-1 levels at the time of renal biopsy. Areas under the receiver operating characteristic curve, comparing baseline creatinine, proteinuria, urinary NRP-1, and VEGFA protein levels, showed NRP-1 to be an independent predictor for clinical response. In addition, in vitro studies suggest that NRP-1could promote renal recovery through endothelial proliferation and migration, mesangial migration and local T cell cytotoxicity. Based on these results, NRP-1 may be used as an early prognostic biomarker in LN.
This work was supported by grants from the Spain Government (Instituto de Salud Carlos III). This research also received donations from Catalan Lupus Foundation and A.Bosch Foundation.
Article
Published version
English
Lupus eritematós sistèmic; Marcadors bioquímics; Prognosi; DISEASES::Immune System Diseases::Autoimmune Diseases::Lupus Erythematosus, Systemic::Lupus Nephritis; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Neuropilins::Neuropilin-1; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis; ENFERMEDADES::enfermedades del sistema inmune::enfermedades autoinmunes::lupus eritematoso sistémico::nefritis lúpica; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::neuropilinas::neuropilina-1; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::Diagnóstico::Pronóstico
MDPI
International Journal of Molecular Sciences;20(18)
https://www.mdpi.com/1422-0067/20/18/4601
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
